Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Our new book is a comprehensive look at a vital part of medicines development and regulatory affairs. Grab your copy today!
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
| 13 November 2013 | By Louise Zornoza,
China's FDA (CFDA) issued a notice on 6 November 2013 establishing a new administrative review process to take effect as of 1 January 2014 allowing entities to appeal decisions.
A requested review must allege that the specific administrative acts infringe upon the legitimate rights and interests of citizens, legal persons or other entities. The burden will be on the applicant to establish the factual and legal basis for the reconsideration of a specific administrative act. Regulators said the administrative review process will be lawful, fair, open and timely, and that the cost of the process will be borne by the CFDA.
Read all Breaking News from Reglink
Tags: Appeals Process